Frontline Treatment in Multiple Myeloma: Treating the Individual Patient
Release Date: January 10, 2018
Expiration Date: January 10, 2019
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In recent years, advances in treatment have resulted in significantly improved outcomes and prognoses in patients with multiple myeloma; much of this research, however, was focused on the population of patients with relapsed or refractory disease. Today, a growing compendium of data and ongoing research is evaluating treatment options and management approaches specifically in patients with newly diagnosed multiple myeloma. The addition of new lenalidomide- and bortezomib-based drug regimens for patients with multiple myeloma increases the complexity of pharmacotherapeutic strategies, which must balance response benefit with tolerability. In addition, there are a number of comorbidities and treatment-related adverse events that must be appropriately assessed and monitored for, to ensure patient safety and prevent premature discontinuation of therapy. In these activities, Dr. Lonial and Dr. Harvey provide an overview of the current and emerging frontline treatment paradigms for multiple myeloma, and discuss how to provide individualized care for patients with comorbid conditions.
This activity is designed for nurses and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Review current and emerging treatment paradigms for patients with newly diagnosed multiple myeloma
- Incorporate evidence-based recommendations for the safe use of lenalidomide- and bortezomib-based treatment in patients with multiple myeloma
- Utilize strategies for the early identification, mitigation, and management of adverse events associated with therapeutic regimens for multiple myeloma
Expanding Treatment Options for Newly Diagnosed Multiple Myeloma: Proteasome Inhibitors, Immunomodulatory Drugs, and Other Targeted Therapies – Sagar Lonial, MD, FACP
Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma – R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Instructions for Participation and Credit
This activity is eligible for credit through January 10, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.
R. Donald Harvey III, PharmD, BCOP, FCCP, FHOPA
Department of Pharmacology
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Dr. R. Donald Harvey received his doctor of pharmacy degree from the University of North Carolina (UNC) at Chapel Hill. He completed a hematology/oncology specialty residency at UNC Hospitals and School of Pharmacy, and a pharmacy practice residency at the University of Kentucky Medical Center and College of Pharmacy. Dr. Harvey is an Associate Professor in the Department of Pharmacology and the Department of Hematology and Medical Oncology at Emory University School of Medicine. In addition, he is Director of the Phase I Clinical Trials Section at the Winship Cancer Institute of Emory University in Atlanta, Georgia.
Dr. Harvey holds memberships in the American Society for Clinical Pharmacology and Therapeutics, International Society of Oncology Pharmacy Practitioners, American Society of Hematology, American Society of Clinical Oncology, Hematology-Oncology Pharmacists Association, and the American College of Clinical Pharmacy. He has published more than 60 peer-reviewed articles and has been a principal or co-investigator on more than 80 early phase trials. Dr. Harvey is on the editorial board of the Journal of Oncology Pharmacy Practice and Pharmacotherapy. In addition, he is a manuscript reviewer for the British Journal of Clinical Pharmacology, Clinical Cancer Research, Investigational New Drugs, British Journal of Cancer, Annals of Oncology, Cancer, and the Journal of Clinical Pharmacology, among others. Dr. Harvey’s research focuses on the application of clinical pharmacology principles to improve cancer treatment outcomes.
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is the Department Chair for Hematology and Medical Oncology at Emory University.
Dr. Lonial serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the Board of Directors for the International Myeloma Society and on the Scientific Advisory Board for the International Myeloma Foundation. Dr. Lonial is the myeloma editor for Clinical Lymphoma and Myeloma and is on the editorial board for the Journal of Clinical Oncology. He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals, and has authored or co-authored over 200 papers and abstracts.
Dr. Lonial has worked in the field of immunotherapy and cancer, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway and the role of 14-3-3 in proteasome function.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-002-071
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sagar Lonial has received honoraria related to formal advisory activities from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb, Celgene, and Takeda Oncology.
Dr. R. Donald Harvey has received honoraria related to formal advisory activities from Aduro Biotech, Bristol-Myers Squibb Company, Huron Pharmaceuticals, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited, as well as consultant fees from Genentech, Inc. He has received grant support related to research activities from AbbVie Inc., Amgen Inc., AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Cleave Biosciences, Calithera BioSciences, Inc., Eli Lilly and Company, Halozyme, Inc., Incyte Corporation, Pfizer Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.